课题基金 / 基金详情

Validation and commercialization of an innovative analgesic for chronic pain

Validation and commercialization of an innovative analgesic for chronic pain
慢性疼痛创新镇痛药的验证和商业化
批准号：
408033
负责人：
Li Shyh-Dar
金额：
$38.18万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-09-01 至 2022-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=408033&lang=en
关键词：
Analgesic Chronic Pain Drug Validation And Commercialization Opioid Crisis

项目摘要

项目成果

Li Shyh-Dar的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Roughly 6 million Canadians report a form of chronic pain, yet half of the sufferers do not get enough pain relief from their medications. This severely affects their quality of life and has significant social and economic burdens. Opioid medications, suc
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of child-friendly oral formulations for drugs used in the maintenance therapy of childhood acute lymphoblastic leukemia
  • 批准号：
    343659
  • 项目类别：
    Operating Grants
  • 资助金额：
    $25.06万
  • 财政年份：
    2016
  • 负责人：
    Li Shyh-Dar
  • 依托单位：
    University of British Columbia
Heat-triggered Chemotherapy to Treat Refractory Breast Cancer at the Chest Wall
Benchmark Cellax, a proprietary nanoparticle formulation for docetaxel, against Taxotere to treat metastatic castration resistant prostate cancer
Targeted Cancer Chemotherapy by Nanoparticle-based Drug Delivery
海外基金